Retina

Delivery into the suprachoroidal space may potentially extend the duration of therapeutic action and reduce or relieve the treatment burden for wet AMD.

Amydis announced the successful completion of a pre-investigational new drug (IND) meeting with the FDA for its candidate AMDX-2011P, a small-molecule retinal tracer that targets amyloid beta to diagnosis amyloid angiopathy.

Two teams of researchers from Gyroscope Therapeutics and the University of Pennsylvania are joining forces to explore gene therapy targets for three specific serious eye diseases.

Study results could provide a new preferred treatment paradigm for this population.

Faricimab is the focus of the YOSEMITE and RHINE studies, which investigators say show that the investigational bispecific antibody has the potential to offer lasting vision improvements for patients with diabetic macular oedema.

Prospective randomised trial demonstrates clinical equivalence of biosimilar and reference ranibizumab

Nine pediatric patients with Leber congenital amaurosis show visual improvement in clinical trials.

All syringes used for intravitreal injections have pros and cons. Some recently marketed and forthcoming products are coming closer to meeting “ideal” criteria.

Novel OCT system with AI-based image analysis holds promise.

With several clinical trials underway, ocular therapy is seen as having potential in the treatment of a number of gene-related diseases.

Protocol T Extension Study details methods needed to maintain VA gains over time.

Interim data from a cross-sectional study raise concerns that repeated intravitreal injections of an anti-VEGF agent may be associated with a decline in cognitive health.

Newest advances improving ophthalmologists’ performance in operating room.

Good early adherence to label regimens can make a difference, yielding vision outcomes approaching those in clinical trials, emerging real-world studies of anti-VEGF for DMO suggest.

As OCT-A devices become faster, the algorithms advance and the instrument costs decrease, more widespread utilisation in retina practices is likely.

Patients with pathogenic variants experience lower VA tied to length of IS/OS junction.

Process eliminates need for expensive in-person examination of patients without DR.

In this roundtable, members of the Ophthalmology Times Europe® Editorial Advisory Board consider the top challenges and opportunities that they anticipate will affect ophthalmology in Europe in 2021.

Advances in treatment and surgical techniques have transformed patient care.

Investigators reviewed visual acuity, multi-modal retinal imaging, electroretinography, family history.

Programs use detection and treatment to ease burden of eye disease.

Investigators looked at trends by geographic variation in practice patterns, perceptions toward opioids, and patient population

Bradley Smith, MD, presents at AAO 2020 on how fingolimod 0.5 mg, a first-line treatment for multiple sclerosis, may reduce both the number of relapses and disease progression in patients with relapsing-remitting MS as well as the incidence of uveitis.

A case series of 13 young patients with Charles Bonnet syndrome, which is characterised by visual hallucinations in individuals who are experiencing sight loss, showed that the patients all had inherited retinal diseases or congenital eye disorders but there was no link with visual dysfunction.

Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.